Gotowa bibliografia na temat „Hepatitis B”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Hepatitis B”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Hepatitis B"
Jain, Ravi, i Ashok Yadav. "Hepatitis B Versus Hepatitis C in Blood Donors". Annals of Applied Bio-Sciences 4, nr 1 (styczeń 2017): A8—A13. http://dx.doi.org/10.21276/aabs.2017.1306.
Pełny tekst źródłaBillah, Mustansar, Syed Muhammad Raza Shah i Muhammad Mujtaba Hashir. "HEPATITIS B AND HEPATITIS C". Professional Medical Journal 25, nr 08 (9.08.2018): 1245–51. http://dx.doi.org/10.29309/tpmj/18.4766.
Pełny tekst źródłaSalam, Abdul, Bilqis Aslam Baloch, Naseer Khan, Ghulam Sarwar i Masoom ,. "SEROPREVALENCE OF HBsAg (HBS) AND ANTI-HCV". Professional Medical Journal 21, nr 04 (7.12.2018): 766–70. http://dx.doi.org/10.29309/tpmj/2014.21.04.2424.
Pełny tekst źródłaDAUD, SEEMA, IRAM MANZOOR i NOREEN RAHAT HASHMI. "PREVENTION OF HEPATITIS B". Professional Medical Journal 14, nr 04 (12.10.2007): 634–38. http://dx.doi.org/10.29309/tpmj/2007.14.04.4829.
Pełny tekst źródłaCano Pina, MB, CM Águila Gordo, P. Dabán López, MP Chas Garibaldi i B. Mirón Pozo. "New therapeutic approaches in Hepatitis B and Hepatitis D". Revista Andaluza de Patología Digestiva 46, nr 6 (2.01.2024): 607–9. http://dx.doi.org/10.37352/2023466.3.
Pełny tekst źródłaEstévez Escobar, M. "New therapeutic approaches in Hepatitis B and Hepatitis D". Revista Andaluza de Patología Digestiva 46, nr 5 (30.10.2023): 258–68. http://dx.doi.org/10.37352/2023465.3.
Pełny tekst źródłaNayak, Akshatha P., Insha Firoz, Ravindra Prabhu, Jayanth Nayak, Veena NK i Megha Nagaraj Nayak. "Development of Immunity to Hepatitis B Virus Following Hepatitis B Vaccination in Hemodialysis Patient". Annals of International Medical and Dental Research 9, nr 2 (kwiecień 2023): 20–23. http://dx.doi.org/10.53339/aimdr.2023.9.2.4.
Pełny tekst źródłaTobokalova, S. T., D. S. Bekenova, G. M. Zairova, Z. Sh Nurmatov, Zh N. Nazarbaeva i Zh T. Aytieva. "Epidemiological features of acute and chronic hepatitis B in the Kyrgyz Republic over the 20-year period (1997-2017)". Kazan medical journal 99, nr 6 (15.12.2018): 986–93. http://dx.doi.org/10.17816/kmj2018-986.
Pełny tekst źródłaViana, Daniel Rodrigues, Nathalia Mundoco Veloso, Osvaldo Carvalho Neto, Nicolas Garcia Papacosta, Gabriel Martins Nunes i Virgílio Ribeiro Guedes. "Hepatite B e C: diagnóstico e tratamento". Revista de Patologia do Tocantins 4, nr 3 (26.09.2017): 73. http://dx.doi.org/10.20873/uft.2446-6492.2017v4n3p73.
Pełny tekst źródłaShahbaz, Tazeem, Ghulam Farid, Raja Sajjad Asghar i Abdul Rashid. "HEPATITIS B AND C". Professional Medical Journal 22, nr 11 (10.11.2015): 1383–89. http://dx.doi.org/10.29309/tpmj/2015.22.11.859.
Pełny tekst źródłaRozprawy doktorskie na temat "Hepatitis B"
Gerlach, Jochen. "Sequenzanalysen von Hepatitis-B-Virusvarianten bei fulminanter Hepatitis B und Hepatitis D". [S.l.] : [s.n.], 1999. http://www.sub.uni-hamburg.de/disse/321/Gerlach.pdf.
Pełny tekst źródłaValente, Vanderleia Barbaro. "Estudo da distribuição dos marcadores sorológicos das hepatites B e C entre doadores de sangue do Hemocentro de Ribeirão Preto, SP". Universidade de São Paulo, 2002. http://www.teses.usp.br/teses/disponiveis/17/17139/tde-29052003-193717/.
Pełny tekst źródłaThis study, which involved all blood donors (25.891) that attended the Blood Center of Ribeirão Preto for the first time from June 1996 to June 2001 had the following objectives: 1) To study the positiveness for hepatitis B and C serologic markers in donors screening tests. 2) To analyze the flow of positive donors for hepatitis B and C markers to the Hepatitis Ambulatory (HA) in the Clinical Hospital of the Faculty of Medicine of Ribeirão Preto of the University of São Paulo. 3) To estimate the predominance of present or former infection by hepatitis B and C viruses among donors, by analyzing results of screening tests that confirm these diseases. 4) To evaluate the importance of determining the glutamic-piruvic transaminase (GTP) as an indirect marker of infection by hepatitis B and C viruses. Registered data from the Blood Center as well as from the Epidemiological Surveillance Nucleus (ESN) and HA were used with the purpose of collecting information about donors, type of donation and results in serologic screening tests (HBsAg, anti-HBc, anti-HCV, GTP, anti-HIV, anti-HTLV, Chagas disease and syphilis). In addition, a study was performed on the results in repetition tests that took place in the Blood Center of positive donors for hepatitis B and C markers in serologic tests as well as on their attendance at the ESN and the confirmation in the HA of the results for these markers. The population of donors was composed in its majority by men (83,6%) and individuals from 26 to 45 year-old (64,0%). Linked donations predominated (85,4%), and the greatest reasons for donation arose from solicitation and stimulus coming from family and friends. The value of prevalence in serologic screening tests was 0,63% (IC95%: 0,54 0,72) for HBsAg and 1,15% (IC95%: 1,02 1,28) for anti-HCV. The total of positive donors that should have been evaluated in the HA suffered a loss of 55,5% among the suspects of having hepatitis B and of 58,7% among the suspects of having hepatitis C, reaching a total of 266 donors lost during follow-up. The value of prevalence in confirmatory tests was 0,22% (IC95%: 0,16 0,28) for hepatitis B and 0,31% (IC95%: 0,24 0,38) for hepatitis C. The copositiveness between GPT and hepatitis markers in serologic screening tests was 8.8% for hepatitis C virus and 0.5% for hepatitis B virus, indicating that determination of this enzyme is not helpful in selection of donors in blood banks.
Umeda, Makoto. "Hepatitis B virus infection in lymphatic tissues in inactive hepatitis B carriers". Kyoto University, 2007. http://hdl.handle.net/2433/135682.
Pełny tekst źródłaArauz-Ruiz, Patricia. "Molecular epidemiology of hepatitis A and hepatitis B virus in central America /". Stockholm : Repro Print, 2002. http://diss.kib.ki.se/2002/91-7349-208-6/.
Pełny tekst źródłaLuo, Ying. "Hepatitis B virus specific immune response after liver transplantation for chronic hepatitis B /". Click to view the E-thesis via HKUTO, 2006. http://sunzi.lib.hku.hk/hkuto/record/B3697724X.
Pełny tekst źródłaLuo, Ying, i 羅英. "Hepatitis B virus: specific immune response after liver transplantation for chronic hepatitis B". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2006. http://hub.hku.hk/bib/B3697724X.
Pełny tekst źródłaKandpal, Manish. "Role of defective hepatitis B virus in wild-type hepatitis B virus replication". Thesis, IIT Delhi, 2017. http://localhost:8080/xmlui/handle/12345678/7247.
Pełny tekst źródłaLu, Lei. "Effects of antiviral therapies on hepatitis B virus relicaptive intermediates in chronic hepatitis B". Click to view the E-thesis via HKUTO, 2009. http://sunzi.lib.hku.hk/hkuto/record/B42182359.
Pełny tekst źródłaSilva, Filho Hermes Pedreira da. "Estudo Molecular dos Vírus B e C das Hepatites nas Regiões Norte e Nordeste do Brasil". reponame:Repositório Institucional da FIOCRUZ, 2010. https://www.arca.fiocruz.br/handle/icict/4219.
Pełny tekst źródłaMade available in DSpace on 2012-07-19T21:21:54Z (GMT). No. of bitstreams: 1 Hermes Pedreira EStudo molecular dos vírus B e C...2010.pdf: 5589974 bytes, checksum: b86706272dbb22d0d349edae7d641ce1 (MD5) Previous issue date: 2010
Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Salvador, Bahia, Brasil
Infecções pelos vírus B e C das hepatites constituem um significante problema de saúde pública em todo mundo. Mais de 350 milhões de pessoas estão cronicamente infectadas pelo VHB e 170 milhões pelo VHC. No Brasil, a prevalência de pessoas infectadas pelo VHB varia de baixa endemicidade (<2%) até alta, (>7%), e estima-se que 1,5% da população esteja infectada pelo VHC (WHO). Estudos recentes tem demonstrado consideráveis variações entre os isolados do VHB, confirmando a diversidade de genótipos do vírus circulantes e o surgimento de mutações no genoma viral que podem ter impacto na resposta terapêutica e imune. Informações sobre a diversidade genética do VHB serão de grande valor para determinar fatores de risco associados a disseminação do vírus e auxiliar na adoção de medidas de prevenção e terapêutica. A infecção pelo VHC tornou-se um sério problema de saude pública desde que não existe uma vacina disponível e o tratamento é extremamente caro para os órgãos públicos como desgastante para o paciente. Este trabalho utilizou as ferramentas moleculares e de epidemiologia no estudo destes vírus para caracterizar molecularmente os vírus B e C das hepatites nas Regiões Norte e Nordeste, particularmente na Bahia, através de sequenciamento de DNA e análises filogenéticas. Amostras de pacientes provenientes da Bahia, Acre, Rondonia, Amazonas, Maranhão e Tocantins foram analisadas. As amostras foram oriundas de outros estudos e de centros de referência para tratamento das hepatites, sendo avaliadas 635 amostras para o VHC e 335 de VHB. Sequencias das regiões pré-S/S e pré- Core/Core do VHB e NS5b, 5UTR, E1 e Core do VHC foram utilizadas para classificação genotípica e análise filogenetica. Os genótipos mais frequentes para o VHB foram A (57%), D (10%) e F(33%) na Bahia e nas amostras da região Norte. Nós encontramos em nosso estudo 55,6% de pacientes co-infectados com VHB/Delta. Não foi possível estabelecer uma ligação genótipo específico com a evolução da infecção, e determinar a presença de mutantes relacionados à resposta terapêutica e ao escape imunológico. Com relação ao VHC, a subtipagem dos isolados foi realizada através do sequenciamento da região NS5b e 5UTR (n=230). Os sub-genótipos mais frequentes foram 1a(45,6%), 1b (46,9%), 3a (6,5%) e 2a/b(0,8%). As regiões E1 e Core também foram sequenciadas e no futuro serão utilizadas para avaliar possiveis mutações. O presente estudo mostra que a aplicação de protocolos de sequenciamento, bioinformática e filogenia são indispensáveis para a compreensão da epidemiologia molecular dos vírus das hepatites.
Infections with hepatitis B and C viruses constitute a significant public health problem worldwide. More than 350 million people are chronically infected with HBV and 170 million by HCV. In Brazil, HBV remains endemic despite widespread vaccination with prevalence of infection ranging from (<2%) low endemicity, until high (>7%) in different regions. Prevalence of HCV infection in Brazil has been estimated at 1.5%. Recent studies have shown considerable genetic variation among HBV isolates, confirming the diversity of circulating genotypes of the virus and the emergence of mutations in the viral genome that may impact on therapeutic and immune response. Information on the genetic diversity of HBV is useful for molecular epidemiology to determine risk factors associated with the spread of the virus and to inform prevention strategies and for monitoring therapy. Because there is no vaccine available to prevent HCV infection and treatment is extremely expensive for public agencies, HCV is an emerging public health problem. The treatment efficiency is directly related to viral genotype. In this study molecular epidemiology tools were used to characterize HBV and HCV in the North and Northeast, particularly in Bahia, through DNA sequencing and phylogenetic analysis. Samples from Bahia, Acre, Rondônia, Amazonas, Maranhão and Tocantins were analyzed. The samples were collected in collaboration with other studies and centers of references for hepatitis treatments. 635 samples from HCV infected patients and 335 samples from HBV infected were evaluated. Sequences of the regions pre-S / S, HBV core / pre-core, NS5B, 5UTR, HCV Core and E1 were used for genotypic classification and phylogenetic analysis. The most frequent HBV genotypes were A (57%), D (10%) and F (33%) in Bahia and in the samples from the North region. Fifty five percent of the patients from Rondônia were coinfected with HBV and HDV. In this study, we were unable to establish a connection with the particular genotype evolution of the infection and determine the presence of mutants related to therapeutic response and immune escape. In the North region co-infection with HBV genotype F and D virus is strongly associated with poor outcome of the disease as informed by the physicians and literature. Regarding HCV, the subtyping of isolates was performed by sequencing the NS5B region and 5UTR (n=230). The sub-genotypes more frequent were 1a (45.6%), 1b (46.9%), 3a (6.5%) and 2a / b (0.8%). The Core and E1 regions were also sequenced and in the future could be used to evaluate possible mutations. This study shows that the implementation of protocols for sequencing, bioinformatics and phylogenetic are essential for understanding the molecular epidemiology of hepatitis.
駱淑芳 i Suk-fong Anna Lok. "Replication of hepatitis B virus in Chinese patients with chronic hepatitis B virus infection". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 1990. http://hub.hku.hk/bib/B31981392.
Pełny tekst źródłaKsiążki na temat "Hepatitis B"
Royal Colleges of Physicians of the United Kingdom. Committee on Health Promotion. Hepatitis B (serum hepatitis). London: Faculty of Community Medicine of the Royal Colleges of Physicians of the United Kingdom, 1985.
Znajdź pełny tekst źródłaFreedman, Jeri. Hepatitis B. New York: Rosen, 2009.
Znajdź pełny tekst źródłaBranch, Canada Health Protection. Hepatitis B. [Ottawa]: Health Protection Branch, 1991.
Znajdź pełny tekst źródłaJ, Gerety R., red. Hepatitis B. Orlando: Academic Press, 1985.
Znajdź pełny tekst źródłaMassachusetts. Department of Public Health. Hepatitis B. Boston, MA: Massachusetts Dept. of Public Health, 1987.
Znajdź pełny tekst źródłaOzaras, Resat, i Veysel Tahan, red. Viral Hepatitis: Chronic Hepatitis B. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-93449-5.
Pełny tekst źródłaGuo, Haitao, i Andrea Cuconati, red. Hepatitis B Virus. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-6700-1.
Pełny tekst źródłaOhio. Perinatal Hepatitis B Prevention i California. Dept. of Health, red. Hepatitis B & pregnancy. Columbus: Ohio Department of Health, 2002.
Znajdź pełny tekst źródłaGuo, Haitao, i Andrea Cuconati, red. Hepatitis B Virus. New York, NY: Springer US, 2024. http://dx.doi.org/10.1007/978-1-0716-4027-2.
Pełny tekst źródłaRajen, Koshy, i Caselmann Wolfgang H, red. Hepatitis B virus: Molecular mechanisms in disease and novel strategies for therapy. London: Imperial College Press, 1998.
Znajdź pełny tekst źródłaCzęści książek na temat "Hepatitis B"
Bastug, Aliye, i Hurrem Bodur. "Acute Hepatitis B". W Viral Hepatitis: Acute Hepatitis, 25–44. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03535-8_3.
Pełny tekst źródłaDoucette, Karen E. "Hepatitis B". W The AST Handbook of Transplant Infections, 61–62. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444397949.ch22.
Pełny tekst źródłaKorn, Klaus. "Hepatitis B". W S2k-Leitlinie - Labordiagnostik schwangerschaftsrelevanter Virusinfektionen, 21–35. Berlin, Heidelberg: Springer Berlin Heidelberg, 2014. http://dx.doi.org/10.1007/978-3-662-43481-9_5.
Pełny tekst źródłaLok, Anna S. F. "Hepatitis B". W Sherlock's Diseases of the Liver and Biliary System, 395–420. Chichester, UK: John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119237662.ch21.
Pełny tekst źródłaBlumberg, Baruch S. "Hepatitis B". W Vaccines: A Biography, 301–15. New York, NY: Springer New York, 2009. http://dx.doi.org/10.1007/978-1-4419-1108-7_17.
Pełny tekst źródłaBonville, Cynthia, i Joseph Domachowske. "Hepatitis B". W Vaccines, 175–87. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-58414-6_14.
Pełny tekst źródłaLok, Anna S. F. "Hepatitis B". W Sherlock's Diseases of the Liver and Biliary System, 367–92. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444341294.ch18.
Pełny tekst źródłaSainburg, Robert L., Andrew L. Clark, George E. Billman, Zachary J. Schlader, Toby Mündel, Kevin Milne, Earl G. Noble i in. "Hepatitis B". W Encyclopedia of Exercise Medicine in Health and Disease, 408. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-540-29807-6_2484.
Pełny tekst źródłaDudley, Matthew Z., Daniel A. Salmon, Neal A. Halsey, Walter A. Orenstein, Rupali J. Limaye, Sean T. O’Leary i Saad B. Omer. "Hepatitis B". W The Clinician’s Vaccine Safety Resource Guide, 51–59. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-94694-8_9.
Pełny tekst źródłaNeumann, G., H. H. Feucht, W. Becker i M. Späth. "Hepatitis B". W Gynäkologische Infektionen, 103–6. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-642-05268-2_29.
Pełny tekst źródłaStreszczenia konferencji na temat "Hepatitis B"
Hussain, Hiba T. H., Arwa Mujahid Abdullah Al-Shuwaikh i Abbas M. Ahmed. "Hepatitis type B virus genotypes in chronic Hepatitis B patients (CHBP)". W 2ND INTERNATIONAL CONFERENCE OF MATHEMATICS, APPLIED SCIENCES, INFORMATION AND COMMUNICATION TECHNOLOGY. AIP Publishing, 2023. http://dx.doi.org/10.1063/5.0162114.
Pełny tekst źródłaTomaz, Isabella Santos, GIOVANNA MATIAS DUARTE, CECILIA BRUNA DE ALMEIDA i LETICIA CRISTINA CHAVES BANDEIRA. "IMUNOPROFILAXIA: PREVENÇÃO DAS HEPATITES VIRAIS". W II Congresso Brasileiro de Imunologia On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/ii-conbrai/6034.
Pełny tekst źródłaEkmen, Onder. "A Case of Fulminant Hepatitis B Reactivation After Hepatitis C Treatment in Hepatitis B+C Co-infection". W 39. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber. Georg Thieme Verlag, 2023. http://dx.doi.org/10.1055/s-0042-1760078.
Pełny tekst źródłaBaraka, Fatiha, Chahrazed Kandouci, Fadela Meflah, Menaouar Rehni i Baderdine Abdelkrim Kandouci. "P086 Hepatitis B and vaccination". W Occupational Health: Think Globally, Act Locally, EPICOH 2016, September 4–7, 2016, Barcelona, Spain. BMJ Publishing Group Ltd, 2016. http://dx.doi.org/10.1136/oemed-2016-103951.407.
Pełny tekst źródłaZamorshchikova, Olga, Snezhana Sleptsova, Keskilene Petrova, Maria Savvina i Spiridon Sleptsov. "Occult Hepatitis B: Case History". W Conference on Health and Wellbeing in Modern Society (CHW 2021). Paris, France: Atlantis Press, 2022. http://dx.doi.org/10.2991/ahsr.k.220103.051.
Pełny tekst źródłaLim, Chee Hooi, i Rajneesh Kumar. "P82 Hepatitis B reactivation in patients with previous hepatitis B exposure; don’t jump, wait". W Abstracts of the BSG Annual Meeting, 20–23 June 2022. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2022. http://dx.doi.org/10.1136/gutjnl-2022-bsg.139.
Pełny tekst źródłaKipiani, E., M. Butsashvili, G. Kamkamidze i G. Abashidze. "STUDY OF RISK FACTORS AFFECTING HBV VACCINE EFFICIENCY AMONG CHILDREN IN GEORGIA". W International Trends in Science and Technology. RS Global Sp. z O.O., 2020. http://dx.doi.org/10.31435/rsglobal_conf/30122020/7346.
Pełny tekst źródłaHattori, M., Y. Ito, S. Takahashi, I. Fukada, T. Iwase, H. Iwata i K. Hatake. "Abstract P5-13-12: Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/ hepatitis B core antibody positive and/or hepatitis B surface antibody positive breast cancer patients who receive chemotherapy". W Abstracts: Thirty-Sixth Annual CTRC-AACR San Antonio Breast Cancer Symposium - Dec 10-14, 2013; San Antonio, TX. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/0008-5472.sabcs13-p5-13-12.
Pełny tekst źródłaSide, Syafruddin, Irwan, Usman Mulbar i Wahidah Sanusi. "SEIR model simulation for Hepatitis B". W 3rd Electronic And Green Materials International Conference 2017 (EGM 2017). Author(s), 2017. http://dx.doi.org/10.1063/1.5002379.
Pełny tekst źródłaSide, Syafruddin, Irwan, Usman Mulbar i Wahidah Sanusi. "SEIR model simulation for Hepatitis B". W 3RD ELECTRONIC AND GREEN MATERIALS INTERNATIONAL CONFERENCE 2017 (EGM 2017). Author(s), 2017. http://dx.doi.org/10.1063/1.5002392.
Pełny tekst źródłaRaporty organizacyjne na temat "Hepatitis B"
Hyams, Kenneth C., Mohamed A. Al-Arabi, Ahmed A. Al-Tagani, James F. Messiter, Abdella A. Al-Gaali i John F. George. Epidemiology of Hepatitis B in the Gezira Region of Sudan. Fort Belvoir, VA: Defense Technical Information Center, styczeń 1989. http://dx.doi.org/10.21236/ada239688.
Pełny tekst źródłaOster, Emily, i Gang Chen. Hepatitis B Does Not Explain Male-Biased Sex Ratios in China. Cambridge, MA: National Bureau of Economic Research, maj 2008. http://dx.doi.org/10.3386/w13971.
Pełny tekst źródłaNguyen, Tung, Mandana Khalili, Janice Tsoh, Judith Walsh, Elizabeth Goldman, Arcadi Kolchak, Ginny Gildengorin, Ching Wong i Ivy Lau. Comparing Ways to Increase Hepatitis B and C Screening Among Asian Americans. Patient-Centered Outcomes Research Institute® (PCORI), marzec 2020. http://dx.doi.org/10.25302/02.2020.ad.12114615.
Pełny tekst źródłaMa, Grace X., Yin Tan, Lin Zhu, Min Qi Wang, Shumenghui Zhai, Jing Yu, Brenda Seals i in. Testing a Program to Help Monitor Chronic Hepatitis B among Asian-American Patients. Patient-Centered Outcomes Research Institute (PCORI), październik 2020. http://dx.doi.org/10.25302/10.2020.ad.140312613.
Pełny tekst źródłaXie, lu, guangwei Liu, pengyu Li, yanan Liu, xinyi He, ruibo Huan i huijun Guo. Analysis of risk factors of chronic hepatitis B patients with Viremia: a meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, lipiec 2023. http://dx.doi.org/10.37766/inplasy2023.7.0107.
Pełny tekst źródłaMa, Yingying. Meta-analysis of the therapeutic effect of Entecavir combined with milk thistle on hepatitis B. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, wrzesień 2023. http://dx.doi.org/10.37766/inplasy2023.9.0043.
Pełny tekst źródłaGoller, Jane, Stephanie Munari, Cassandra Caddy, Teralynn Ludwick, Jacqueline Coombe, Meredith Temple-Smith, Lena Sanci i Jane Hocking. General Practice engagement: STI, HIV and viral hepatitis care. The Sax Institute, czerwiec 2023. http://dx.doi.org/10.57022/lnur4773.
Pełny tekst źródłaZeng, Hua, i Yuanliang Liu. Entecavir in the treatment of chronic hepatitis B in children and adolescents:Systematic review and meta-analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, maj 2020. http://dx.doi.org/10.37766/inplasy2020.5.0112.
Pełny tekst źródłaKancheva, Lyudmila, Petar Nikolov, Tsvetelina Velikova, Ivan Valkov, Rossen Nikolov i Lyudmila Mateva. Soluble CD14 is Associated with Disease Activity and Severity in Chronic Viral Hepatitis C and B. "Prof. Marin Drinov" Publishing House of Bulgarian Academy of Sciences, czerwiec 2018. http://dx.doi.org/10.7546/crabs.2018.06.17.
Pełny tekst źródłaZhang, JunLI, HongYuan Mou, Ying He i XiaoYu Hu. Fuzheng Huayu Combined with Tenofovir Disoproxil Fumarate for Hepatitis B: A Systematic Review and Meta-Analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, listopad 2021. http://dx.doi.org/10.37766/inplasy2021.11.0002.
Pełny tekst źródła